Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers

The steady-state kinetics of chlorophenoxyisobuytric acid (CPIB) and of bezafibrate were investigated in a strictly controlled, randomised cross-over study in 10 female volunteers, after the conventional oral doses of clofibrate 0.5 g and bezafibrate f0.2 g at 8-h intervals. The mean steady-state co...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of clinical pharmacology 1980-04, Vol.17 (4), p.305-308
Hauptverfasser: Abshagen, U, Spörl-Radun, S, Marinow, J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 308
container_issue 4
container_start_page 305
container_title European journal of clinical pharmacology
container_volume 17
creator Abshagen, U
Spörl-Radun, S
Marinow, J
description The steady-state kinetics of chlorophenoxyisobuytric acid (CPIB) and of bezafibrate were investigated in a strictly controlled, randomised cross-over study in 10 female volunteers, after the conventional oral doses of clofibrate 0.5 g and bezafibrate f0.2 g at 8-h intervals. The mean steady-state concentration of CPIB in serum was 34 times higher than that of bezafibrate, which was due to the considerable cumulation of CPIB, whereas no cumulation of bezafibrate was observed. This is supported by comparison of the AUCs, and of the maximum and mean concentrations of bezafibrate after the first and last doses. beta (0.44 and 0.49 h(-1)) and the half-lives (1.6 and 1.4h) were almost identical after the first and last doses of bezafibrate. The median total clearances of CPIB and bezafibrate amounted to 10.5 and 142.5ml/min, respectively, if complete absorption of both drugs is assumed. Since the apparent volumes of distribution were in the same range for both drugs, the amount of drug present in the organism in steady-state also differed by a factor of approximately 30 under the usual dosage regimen.
doi_str_mv 10.1007/BF00625805
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_75193846</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75193846</sourcerecordid><originalsourceid>FETCH-LOGICAL-c282t-1012dcf462b8f47f8f69345e02b9ca9150df20471311113a0b97e228edd4bcdc3</originalsourceid><addsrcrecordid>eNpFkE1Lw0AQhhdRaq1evAs5eRCis19J9qjFqlBQUM9hP2ZpNB-a3Qj115vSqnMZZnh4eXkIOaVwSQHyq5sFQMZkAXKPTKngLKUg6D6ZAnCaZiqHQ3IUwhsAlQr4hEwypSTldEqeniNqt05D1BGT96rFWNmQdD4x-K19ZfrNX7cusXX3e1ZtskJdx9U68djoGpOvrh7aiNiHY3LgdR3wZLdn5HVx-zK_T5ePdw_z62VqWcHiWJAyZ73ImCm8yH3hM8WFRGBGWa2oBOcZiHwsOQ7XYFSOjBXonDDWWT4j59vcj777HDDEsqmCxbrWLXZDKHNJFS9ENoIXW9D2XQg9-vKjrxrdr0sK5UZf-a9vhM92qYNp0P2hO1_8B48Waeg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75193846</pqid></control><display><type>article</type><title>Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Abshagen, U ; Spörl-Radun, S ; Marinow, J</creator><creatorcontrib>Abshagen, U ; Spörl-Radun, S ; Marinow, J</creatorcontrib><description>The steady-state kinetics of chlorophenoxyisobuytric acid (CPIB) and of bezafibrate were investigated in a strictly controlled, randomised cross-over study in 10 female volunteers, after the conventional oral doses of clofibrate 0.5 g and bezafibrate f0.2 g at 8-h intervals. The mean steady-state concentration of CPIB in serum was 34 times higher than that of bezafibrate, which was due to the considerable cumulation of CPIB, whereas no cumulation of bezafibrate was observed. This is supported by comparison of the AUCs, and of the maximum and mean concentrations of bezafibrate after the first and last doses. beta (0.44 and 0.49 h(-1)) and the half-lives (1.6 and 1.4h) were almost identical after the first and last doses of bezafibrate. The median total clearances of CPIB and bezafibrate amounted to 10.5 and 142.5ml/min, respectively, if complete absorption of both drugs is assumed. Since the apparent volumes of distribution were in the same range for both drugs, the amount of drug present in the organism in steady-state also differed by a factor of approximately 30 under the usual dosage regimen.</description><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/BF00625805</identifier><identifier>PMID: 6995131</identifier><language>eng</language><publisher>Germany</publisher><subject>Administration, Oral ; Adult ; Bezafibrate ; Clinical Trials as Topic ; Clofibrate - administration &amp; dosage ; Clofibrate - analogs &amp; derivatives ; Clofibrate - blood ; Clofibrate - metabolism ; Clofibric Acid - administration &amp; dosage ; Clofibric Acid - analogs &amp; derivatives ; Clofibric Acid - blood ; Clofibric Acid - metabolism ; Drug Administration Schedule ; Female ; Half-Life ; Humans ; Hypolipidemic Agents - administration &amp; dosage ; Hypolipidemic Agents - blood ; Hypolipidemic Agents - metabolism ; Kinetics</subject><ispartof>European journal of clinical pharmacology, 1980-04, Vol.17 (4), p.305-308</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c282t-1012dcf462b8f47f8f69345e02b9ca9150df20471311113a0b97e228edd4bcdc3</citedby><cites>FETCH-LOGICAL-c282t-1012dcf462b8f47f8f69345e02b9ca9150df20471311113a0b97e228edd4bcdc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6995131$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abshagen, U</creatorcontrib><creatorcontrib>Spörl-Radun, S</creatorcontrib><creatorcontrib>Marinow, J</creatorcontrib><title>Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><description>The steady-state kinetics of chlorophenoxyisobuytric acid (CPIB) and of bezafibrate were investigated in a strictly controlled, randomised cross-over study in 10 female volunteers, after the conventional oral doses of clofibrate 0.5 g and bezafibrate f0.2 g at 8-h intervals. The mean steady-state concentration of CPIB in serum was 34 times higher than that of bezafibrate, which was due to the considerable cumulation of CPIB, whereas no cumulation of bezafibrate was observed. This is supported by comparison of the AUCs, and of the maximum and mean concentrations of bezafibrate after the first and last doses. beta (0.44 and 0.49 h(-1)) and the half-lives (1.6 and 1.4h) were almost identical after the first and last doses of bezafibrate. The median total clearances of CPIB and bezafibrate amounted to 10.5 and 142.5ml/min, respectively, if complete absorption of both drugs is assumed. Since the apparent volumes of distribution were in the same range for both drugs, the amount of drug present in the organism in steady-state also differed by a factor of approximately 30 under the usual dosage regimen.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Bezafibrate</subject><subject>Clinical Trials as Topic</subject><subject>Clofibrate - administration &amp; dosage</subject><subject>Clofibrate - analogs &amp; derivatives</subject><subject>Clofibrate - blood</subject><subject>Clofibrate - metabolism</subject><subject>Clofibric Acid - administration &amp; dosage</subject><subject>Clofibric Acid - analogs &amp; derivatives</subject><subject>Clofibric Acid - blood</subject><subject>Clofibric Acid - metabolism</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Half-Life</subject><subject>Humans</subject><subject>Hypolipidemic Agents - administration &amp; dosage</subject><subject>Hypolipidemic Agents - blood</subject><subject>Hypolipidemic Agents - metabolism</subject><subject>Kinetics</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1980</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1Lw0AQhhdRaq1evAs5eRCis19J9qjFqlBQUM9hP2ZpNB-a3Qj115vSqnMZZnh4eXkIOaVwSQHyq5sFQMZkAXKPTKngLKUg6D6ZAnCaZiqHQ3IUwhsAlQr4hEwypSTldEqeniNqt05D1BGT96rFWNmQdD4x-K19ZfrNX7cusXX3e1ZtskJdx9U68djoGpOvrh7aiNiHY3LgdR3wZLdn5HVx-zK_T5ePdw_z62VqWcHiWJAyZ73ImCm8yH3hM8WFRGBGWa2oBOcZiHwsOQ7XYFSOjBXonDDWWT4j59vcj777HDDEsqmCxbrWLXZDKHNJFS9ENoIXW9D2XQg9-vKjrxrdr0sK5UZf-a9vhM92qYNp0P2hO1_8B48Waeg</recordid><startdate>198004</startdate><enddate>198004</enddate><creator>Abshagen, U</creator><creator>Spörl-Radun, S</creator><creator>Marinow, J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198004</creationdate><title>Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers</title><author>Abshagen, U ; Spörl-Radun, S ; Marinow, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c282t-1012dcf462b8f47f8f69345e02b9ca9150df20471311113a0b97e228edd4bcdc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1980</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Bezafibrate</topic><topic>Clinical Trials as Topic</topic><topic>Clofibrate - administration &amp; dosage</topic><topic>Clofibrate - analogs &amp; derivatives</topic><topic>Clofibrate - blood</topic><topic>Clofibrate - metabolism</topic><topic>Clofibric Acid - administration &amp; dosage</topic><topic>Clofibric Acid - analogs &amp; derivatives</topic><topic>Clofibric Acid - blood</topic><topic>Clofibric Acid - metabolism</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Half-Life</topic><topic>Humans</topic><topic>Hypolipidemic Agents - administration &amp; dosage</topic><topic>Hypolipidemic Agents - blood</topic><topic>Hypolipidemic Agents - metabolism</topic><topic>Kinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abshagen, U</creatorcontrib><creatorcontrib>Spörl-Radun, S</creatorcontrib><creatorcontrib>Marinow, J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abshagen, U</au><au>Spörl-Radun, S</au><au>Marinow, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers</atitle><jtitle>European journal of clinical pharmacology</jtitle><addtitle>Eur J Clin Pharmacol</addtitle><date>1980-04</date><risdate>1980</risdate><volume>17</volume><issue>4</issue><spage>305</spage><epage>308</epage><pages>305-308</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><abstract>The steady-state kinetics of chlorophenoxyisobuytric acid (CPIB) and of bezafibrate were investigated in a strictly controlled, randomised cross-over study in 10 female volunteers, after the conventional oral doses of clofibrate 0.5 g and bezafibrate f0.2 g at 8-h intervals. The mean steady-state concentration of CPIB in serum was 34 times higher than that of bezafibrate, which was due to the considerable cumulation of CPIB, whereas no cumulation of bezafibrate was observed. This is supported by comparison of the AUCs, and of the maximum and mean concentrations of bezafibrate after the first and last doses. beta (0.44 and 0.49 h(-1)) and the half-lives (1.6 and 1.4h) were almost identical after the first and last doses of bezafibrate. The median total clearances of CPIB and bezafibrate amounted to 10.5 and 142.5ml/min, respectively, if complete absorption of both drugs is assumed. Since the apparent volumes of distribution were in the same range for both drugs, the amount of drug present in the organism in steady-state also differed by a factor of approximately 30 under the usual dosage regimen.</abstract><cop>Germany</cop><pmid>6995131</pmid><doi>10.1007/BF00625805</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0031-6970
ispartof European journal of clinical pharmacology, 1980-04, Vol.17 (4), p.305-308
issn 0031-6970
1432-1041
language eng
recordid cdi_proquest_miscellaneous_75193846
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Administration, Oral
Adult
Bezafibrate
Clinical Trials as Topic
Clofibrate - administration & dosage
Clofibrate - analogs & derivatives
Clofibrate - blood
Clofibrate - metabolism
Clofibric Acid - administration & dosage
Clofibric Acid - analogs & derivatives
Clofibric Acid - blood
Clofibric Acid - metabolism
Drug Administration Schedule
Female
Half-Life
Humans
Hypolipidemic Agents - administration & dosage
Hypolipidemic Agents - blood
Hypolipidemic Agents - metabolism
Kinetics
title Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T21%3A34%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Steady-state%20kinetics%20of%20bezafibrate%20and%20clofibrate%20in%20healthy%20female%20volunteers&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=Abshagen,%20U&rft.date=1980-04&rft.volume=17&rft.issue=4&rft.spage=305&rft.epage=308&rft.pages=305-308&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/BF00625805&rft_dat=%3Cproquest_cross%3E75193846%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75193846&rft_id=info:pmid/6995131&rfr_iscdi=true